JNJ

237.61

+1.2%↑

UNH

266.5

-4.07%↓

TMO

546.08

-3.61%↓

ABT

109.17

+0.16%↑

ISRG

476.92

-0.47%↓

JNJ

237.61

+1.2%↑

UNH

266.5

-4.07%↓

TMO

546.08

-3.61%↓

ABT

109.17

+0.16%↑

ISRG

476.92

-0.47%↓

JNJ

237.61

+1.2%↑

UNH

266.5

-4.07%↓

TMO

546.08

-3.61%↓

ABT

109.17

+0.16%↑

ISRG

476.92

-0.47%↓

JNJ

237.61

+1.2%↑

UNH

266.5

-4.07%↓

TMO

546.08

-3.61%↓

ABT

109.17

+0.16%↑

ISRG

476.92

-0.47%↓

JNJ

237.61

+1.2%↑

UNH

266.5

-4.07%↓

TMO

546.08

-3.61%↓

ABT

109.17

+0.16%↑

ISRG

476.92

-0.47%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Открыт

3.16 -3.07

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.14

Макс.

3.2800000000000002

Ключевые показатели

By Trading Economics

Доход

44M

-26M

Продажи

-5.8M

42M

Рентабельность продаж

-61.388

Сотрудники

550

EBITDA

44M

-22M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+30.37% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

17 мар. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

159M

1.2B

Предыдущая цена открытия

6.23

Предыдущая цена закрытия

3.16

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

5 февр. 2026 г., 00:00 UTC

Популярные акции

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 февр. 2026 г., 22:55 UTC

Отчет

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 февр. 2026 г., 21:44 UTC

Отчет

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 февр. 2026 г., 21:39 UTC

Отчет

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 февр. 2026 г., 00:00 UTC

Отчет

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 февр. 2026 г., 00:00 UTC

Отчет

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 февр. 2026 г., 23:46 UTC

Обсуждения рынка

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 февр. 2026 г., 23:45 UTC

Отчет

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 февр. 2026 г., 23:32 UTC

Обсуждения рынка

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 февр. 2026 г., 22:59 UTC

Приобретения, слияния, поглощения

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 февр. 2026 г., 22:30 UTC

Отчет

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 февр. 2026 г., 22:30 UTC

Отчет

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 февр. 2026 г., 22:21 UTC

Отчет

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 февр. 2026 г., 22:17 UTC

Обсуждения рынка

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 февр. 2026 г., 22:15 UTC

Обсуждения рынка

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 февр. 2026 г., 22:00 UTC

Обсуждения рынка

ESG Roundup: Market Talk

4 февр. 2026 г., 21:53 UTC

Отчет

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 февр. 2026 г., 21:51 UTC

Отчет

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

4 февр. 2026 г., 21:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Financial Services Roundup: Market Talk

4 февр. 2026 г., 21:50 UTC

Обсуждения рынка
Отчет

Auto & Transport Roundup: Market Talk

4 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

4 февр. 2026 г., 21:45 UTC

Отчет

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 февр. 2026 г., 21:44 UTC

Отчет

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 февр. 2026 г., 21:43 UTC

Отчет

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 февр. 2026 г., 21:41 UTC

Отчет

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 февр. 2026 г., 21:36 UTC

Обсуждения рынка

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 февр. 2026 г., 21:30 UTC

Отчет

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 февр. 2026 г., 21:30 UTC

Отчет

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 февр. 2026 г., 21:30 UTC

Отчет

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Сравнение c конкурентами

Изменение цены

Maravai LifeSciences Holdings Inc (Class A) Прогноз

Целевая цена

By TipRanks

30.37% рост

Прогноз на 12 месяцев

Средняя 4.25 USD  30.37%

Максимум 4.5 USD

Минимум 4 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Maravai LifeSciences Holdings Inc (Class A) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

4 ratings

3

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

2.02 / 2.115Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Strong Bullish Evidence

Долгосрочная

No Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat